Mandy Jackson

Obesity biotech Kailera Therapeutics files for a $100 million IPO $KLRA $IPO #IPO zpr.io/KSKqsVXbDgCk

$XBI is down 2.5% today and 0.7% year-to-date after the Fed held interest rates steady. It’s been a volatile year so far for biopharma after an optimistic start to 2025.

The scariest consequence of climate change yet … 😬😳🐍 This assuages my guilt somewhat that it’s warmer here than almost anywhere in the US right now. Stay cool San Diego.

Asthma-focused AI biotech Generate Biomedicines sets terms for $400 million IPO $GENB $IPO #IPO zpr.io/cQvAuVBBfaHp

Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end $EIKN $IPO #IPO zpr.io/wAvgrr9a5EMt

Hair loss biotech Veradermics prices upsized IPO at $17, above the range $MANE $IPO #IPO zpr.io/jTj9vid3fw95

Does anyone have good suggestions for organizations or advocacy groups that can offer advice on options for assisted living or group home care for elderly, disabled couples, including a veteran, who would not meet low income standards but also are not wealthy?

Three #biopharma IPOs on deck for next week.

Immuno-responsive cancer biotech Eikon Therapeutics sets terms for $300 million IPO $EIKN $IPO #IPO zpr.io/AqZPvLr86VLK

BioVie liver disease carve-out Option Therapeutics files and sets terms for a $25 million IPO $OPTN $IPO #IPO zpr.io/TrJL2VTeaGdx

If you need a break from the news & you’re stuck inside because of the storms, now might be a good time to check out the the podcast Jessica Merrill & I from Scrip & David Wild from In Vivo recorded to talk about what we heard at #JPM26 & Biotech Showcase. insights.citeline.com/scrip/podcasts…

Scrip’s #JPM26 Day 4 coverage is ready early - insights from Novo, Bayer, Novavax and BI. insights.citeline.com/scrip/conferen…

Scrip’s #JPM26 Day 3 coverage includes commentary from Sanofi, BMS, Boehringer Ingelheim, Gilead, AstraZeneca and GSK, free to read without a subscription. insights.citeline.com/scrip/conferen…

Scrip’s #JPM26 Day One coverage is free to read without a subscription. insights.citeline.com/scrip/conferen…

ICYMI #JPM26 day 2 coverage from Scrip. More to come today/tomorrow.

$XBI Down 1.7% with no biopharma M&A announced on the first morning of #JPM26

$ABBV Paying $650m up front and up to $4.95bn in milestone fees for a PD-1/VEGF bispecific.

Will 2026 outpace the meager 13 biopharma IPOs on Western exchanges in 2025 (12 in US and 1 in Europe)? Or will Hong Kong become the next big IPO market after 20 biopharma firms went public on Asian exchanges last year, including US-based Insilico? insights.citeline.com/scrip/business…

I also looked back at Q4 2025 VC data last week: $8.04bn raised by drug developers during the quarter, according to Evaluate Pharma. The biggest single quarter since 2022, but it still wasn’t enough for last year to beat full year 2024. insights.citeline.com/scrip/business…

About to fly SAN-SFO for #JPM26, thinking about what’s ahead this week, including biopharma M&A chatter and capital markets predictions. By my count, 9 drug developers raised $2.87bn in significant follow-on offerings and PIPEs during the week before JPM. insights.citeline.com/scrip/business…